TABLE 3.

Multivariable logistic regression model addressing the influence of the type of vaccination and the use of mycophenolate for developing anti‐spike IgG, adjusted for body mass index and time between doses

Variable	OR (95% CI)	p value
Body mass index	0.426 (0.234–0.771)	0.005 a
Vaccine type
ChAdOx1 (AstraZeneca)	[Ref.]	[Ref.]
BBIBP CorV (Sinopharm)	1.256 (0.414–3.808)	0.687
rAd26‐rAd5 (Sputnik V)	1.814 (0.605–5.432)	0.287
rAd26/mRNA‐1273 (Sputnik V/Moderna)	13.138 (2.368–72.891)	0.003 a
Mycophenolate use
No mycophenolate	[Ref.]	[Ref.]
Mycophenolate dose ≤1000 mg	0.262 (0.083–0.820)	0.021 a
Mycophenolate dose >1000 mg	0.117 (0.036–0.376)	<0.001 a
Time between vaccine doses	1.502 (0.691–3.265)	0.304

Abbreviations: CI, confidence interval; IgG, immunoglobulin G; OR, odds ratio; Ref., reference.

^a p value is significant.